LAMP - 631629 - Biotech pur Sammelthread - 500 Beiträge pro Seite

[GuenterNetzer]

LAMP

In diesem thread sollen nach Möglichkeit einigermaßen sortiert alle Infos zu LAMP zusammengetragen werden.

Am besten fängt man mit den letzten beiden NEWS von heute an

1.)

New Research Report Issued on LAM Pharmaceutical Corp.

LEWISTON, N.Y., March 7 /PRNewswire-FirstCall/ -- LAM Pharmaceutical Corp. (OTC Bulletin Board: LAMP; FRANKFURT STOCK EXCHANGE: LAM), http://www.lampharm.com, announced today that a Research Report on the Company has been issued by General Research GmbH of Munich, Germany.

The thirty page Research Report was prepared in German and is posted on the Company`s website. The Report recommends a Long Term Buy Rating for the Company`s common stock and projects, milestone driven, improvements in stock prices and overall capitalization.

General Research GmbH is one of Germany`s most highly respected Research Publication firms. Their chief analyst, Dr. Georg Hochwimmer, has a PhD. in Biochemistry and advanced credentials in business. General Research GmbH`s many subscribers closely follow the recommendations of Dr. Hochwimmer.

Alan Drizen, CEO of LAM Pharmaceutical Corp. said, "Dr. Hochwimmer`s reputation and credibility for preparing well-researched and balanced Research Reports, enhances the value of his recommendations. We believe his conclusions have captured the essence of our proprietary technology and his strong support for the Company`s future growth are well justified.

LAM Pharmaceutical Corp. is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original Ionic Polymer Matrix(TM) technology (IPM(TM)), a proprietary and patented combination (a total of nine U.S. issued patents) of electrically charged and non-charged molecules with wound-healing properties. IPM(TM) technology combines with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible and thus prolonging therapeutic activity.

The main ingredient of the Ionic Polymer Matrix(TM) technology is a derivative of hyaluronic acid, a molecule normally found in the skin and joints of bones. Hyaluronic acid is a non-immunogenic (the body does not react to it) and it is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars) to optimize tissue repair and prevent tissue aging. As well, hyaluronic acid is present in high concentration in fetal skin where wound healing is rapid and leaves little scarring.

LAM IPM(TM) Wound Gel is a clear, viscous, aqueous, odorless gel composed principally of sodium hyaluronate, a derivative salt of Hyaluronic acid. LAM IPM(TM) Wound Gel has demonstrated in both human and animal trials to be of significant value in the management of certain skin ulcers and wounds where maintaining a moist environment is supportive of the healing process. In human skin, Hyaluronic acid is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars).

As of December 31, 2001, LAM had nine issued patents in the United States. LAM IPM(TM) Wound Gel is protected by one or more of the following patents: 5,887,880; 6,120,804; 6,007,843; 6,063,405. All referenced patents have been issued to LAM Pharmaceutical Corp. by the United States Patent Office and have subsequently been filed on a global basis.

The Company`s list of products under development include the following:

LAM IPM(TM) -- Extreme Dry Skin Formula -- A gel formula designed to
saturate the stratum corneum, to relieve the symptoms of eczema,
dermatitis and extremely dry skin.

LAM IPM(TM) -- Female Sexual Dysfunction Matrix -- a product that
provides enhanced lubrication while also allowing the external structures
of the female genitalia to be flushed with greater blood supply.

LAM IPM(TM) -- Motion Sickness Matrix -- a product currently under
development, which is a topically applied delivery system, using a patch,
of a well-known motion sickness drug.

LAM IPM(TM) -- Arthritic Pain Matrix -- is a clear aqueous gel that
contains a well proven off patent drug.


For more information please visit our website at http://www.lampharm.com or send us an e-mail at [e-mail] to receive the latest information and press releases.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company`s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

Company Contact: Anthony Vespa
Toll Free in North America [phone]
Fax [phone]
Website: http://www.lampharm.com

Press Contact: Barry S. Kaplan
Barry Kaplan Associates
[phone]
FAX [phone]
Email: [e-mail]

Research Report Contact: General Research GmbH
Dr. Georg Hochwimmer
Tel [phone]
Fax [phone]
[e-mail]

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X21244535

2.)

TheSUBWAY.com Announces Investment Opinion: Financial Targets


NOTE TO EDITORS: The Following Is An Investment Opinion Issued By TheSUBWAY.com

WESTON, FL, Mar 07, 2002 (INTERNET WIRE via COMTEX) -- Keep an eye on LAM Pharmaceutical Corp. (OTCBB: LAMP). The company just released big news. LAMP is down from almost $6.50 and could be a huge gainer in the short term. Other stock market standouts include Dell Computer Corporation (Nasdaq: DELL), up 1% on 20 million shares after being chosen for $25 million Technology Initiative for Oklahoma City Schools, Leap Wireless International (Nasdaq: LWIN), up 35% on 6 million shares and Allegiance Telecom Inc. (Nasdaq: ALGX), up 13% on 4 million shares after completing electronic link with Verizon Wholesale Systems.
"Shares of McData tumbled as much as 25 percent after the Company warned late Tuesday that it would not meet Wall Street`s financial targets for the first quarter, citing cautious spending on technology products by larger customers. On the flip-side, Sprint`s announcement that it was on track to meet 2002 financial targets gave Sprint shares almost a 10 percent hike, while other stocks in the space enjoyed similar gains." Stated Peter Antipatis in TheSUBWAY.com`s daily commentary. Continued at www.TheSUBWAY.com.



GN

[morchel]

Am Besten man stellt dann noch ein paar Links rein:

http://www.lampharm.com/reports/research_lamp_4.pdf ...der brandheisse Resarch Report von heute!

http://www.zockstocks.com/Vorstellungen/LAMP/LAMP.htm ...den Report den ich schon viel früher erstellte

Die Webseite:
http://www.lampharm.com

einen Chart:



morchel

[GuenterNetzer]

@morchel

Darf man Dich denn wegen Deines Reports Dr. morchel nennen?

Meine Theorie ist, daß die Aktie aufgrund des Reports in Deutschland bald höhere Volumina haben wird als in USA...

GN

[morchel]

...natürlich darfst du!

vor allem die ersten Zeilen sind verdächtig ähnlich den meines Reports! Hat der Dr. abgekupfert?

....nein sicher nicht!


(Dr.)morchel

[GuenterNetzer]

@morchel

Also Doc, ich werde morgen dafür sorgen, daß in Frankfurt über 100K Stücke gehandelt werden...und zwar keine trader-Ware, sondern gute kräftige Investments.



GN

[morchel]

....super Trainer! Ich hoffe du hast finanzkräftige Investoren in deiner Aufstellung, Trainer1

[KaterLudwig]

@GN

...also Morgen 100K, und Du bekommst nen ONLINE COFFEE von mir

[GuenterNetzer]

@KaterLudwig

Na dann setz schon mal Wasser auf...und bitte nur die Dröhnung, den Besten vom Kater.



GN

[Misterproject]

@Guenter
Du bist ein Riesenschwätzer und nichts dahinter IBUI hast du gross gepriesen und MCLD hasst du mir vor der Pleite
eingeschwätzt und was kommt noch? Du hasst doch eine Firma, wie hiess sie noch Inv...
Good?

[GuenterNetzer]

@Misterproject

Danke, Du bist ein echter Freund!

GN

[Misterproject]

@Guenter
Ich war nie dein Freund. Deine Empfehlungen treffen leider in letzter Zeit ins Abseits. Morchel ist der OTC Spezialist
der Rest Apfelmuss
Good Food

[morchel]

Vieleicht solltet ihr euch mal die Lebensgeschichten vom CEO Alan Drizen anschauen (wird übrigends in Report kurz angeschnitten)

Der Mann ist wirklich TOP!

hat aus dem Nichts ein Unternehmen gegründet das einen Börsenwert von 1 Mrd USD hatte! Das soll ihm erst einer mal nachmachen!

Der Vergleich mit MSFT ist als nocht so weit hergeholt wie man meint!

morchel

[KaterLudwig]

@GN

...schade um das Kaffeewasser

[GuenterNetzer]

@KaterLudwig

Gibt es denn für die 60K wenigstens einen Espresso?



GN

[KaterLudwig]

@GN
...sicher...


Schönes WE

MFG

[GuenterNetzer]

LAMP

Heute sieht es ja ganz gut aus bei LAMP`s...

15.03.2002, 16:51 pm
LAMP OTCBB $ 0.74 / +0.04 / +5.71% / Volume:20,100

Dr. morchel bitte auf Station 4, gibt es bald was Neues???

GN

[GuenterNetzer]

LAM PHARMACEUTICAL CORP files Prospectus Pursuant to Rule 424

--------------------------------------------------------------------------------


Filed Pursuant to Rule 424(b)(3)
Registration No. 333-56390


L.A.M. PHARMACEUTICAL, CORP.

Prospectus Supplement
(To Prospectus Dated June 7, 2001)
Prospective investors should read this prospectus supplement and the related prospectus carefully before investing in L.A.M.`s common stock. Both documents contain information prospective investors should consider when making an investment decision.

The attached prospectus relates to the resale of shares acquired by Hockbury Limited pursuant to an equity line of credit. Because Hockbury Limited may sell some or all of these shares, and because there are currently no agreements, arrangements or understandings with respect to the sale of any of these shares, L.A.M. cannot estimate the actual number of shares that Hockbury Limited will hold after the completion of the offering.

The following provides information concerning the latest drawdown requested by L.A.M.


Date of Date of Shares Average Sale Net Proceeds
Request Sale Sold Price Per Share to L.A.M.
------- ------- ------ --------------- ------------

2-08-02 3/12/02 143,185 $0.64 $ 92,000




The proceeds to L.A.M. are net of the 7% placement agent fee paid to GKN Securities. GKN Securities is the placement agent which introduced Hockbury Limited to L.A.M. and is a registered broker-dealer.
L.A.M.`s common stock is quoted on the OTC Bulletin Board under the symbol "LAMP". On March 12, 2002 the closing price for one share of L.A.M.`s common stock was $0.72.

L.A.M. expects to use the proceeds from the sale of these shares for general and administrative expenses, research, clinical trials and sales and marketing.

The date of this prospectus supplement is March 12, 2002.

Dr. morchel, bitte in den OP.



GN

[GuenterNetzer]

LAMP

Mit dieser NEWS wird ein wichtiger Schritt in die Zukunft bestätigt:

March 19, 2002 07:01

LAM Pharmaceutical Corp. - LAM IPM(TM) Wound Gel Product Status Update on Pre-Marketing Notification 510(k) Filed With FDA
Jump to first matched term

LEWISTON, N.Y., March 19 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM), http://www.lampharm.com issued the following update concerning the current status of LAM IPM(TM) Wound Gel. On January 31, 2002 LAM Pharmaceutical, Corp. filed a 510(k) pre-market notification with the Food and Drug Administration in the United States for LAM IPM(TM) Wound Gel.

The FDA has assigned the following number to the 510(k) pre-market notification - K020325.

Formerly known as "LAM Ulcer Matrix," the product is now known as LAM IPM(TM) Wound Gel.

Under F.D.A. guidelines, the Company expects to receive a decision by April 30, 2002 regarding the status of LAM IPM(TM) Wound Gel`s suitability to be marketed.

Under supervision of a healthcare professional, LAM IPM(TM) Wound Gel is suitable for exuding wounds such as:

* Diabetic ulcers
* Leg ulcers
* Pressure ulcers
* Management of wounds that are prone to bleeding, such as wounds that
have been mechanically or surgically debrided.

LAM`s Chief Executive Officer, Alan Drizen, said, "We are excited and most proud that eight years of research and development have brought us to this important juncture where the results of our hard work are allowing us to commercialize our proprietary and patented technologies."

As promised, the company has delivered on completing the following important steps to help ensure the success of its first commercial product. These include:

* Richard Brokenshire joined LAM in the newly created position as
Vice President, Sales & Marketing.
* LAM signed an agreement to register IPM(TM) Wound Gel in Mexico.
* Exygen Research was appointed as quality control specialists and
will provide analytical and other technical services to assist in
the commercialization of LAM`s entire product portfolio.
* LAM signed a marketing agreement with RxCentric Inc. of New York
City.
* Packaging design for IPM(TM) Wound Gel has been completed.

In the Company`s opinion, revenue forecasts of US$ 27.0 million for 2003 and US$ 50.0 million for 2004 calendar year are both realistic and achievable, given the size (U.S. 2.5 billion plus) of the wound care market segment on which LAM IPM(TM) Wound Gel impacts.

"This 510(k) submission is a critical milestone for LAM Pharmaceutical, Corp.," Joseph Slechta, President & Chief Operating Officer commented. "With anticipated FDA clearance of LAM IPM(TM) Wound Gel, LAM has successfully initiated manufacturing, marketing and distribution channels which will position the Company to begin sales of the product in the early part of the third quarter 2002. Revenues should commence within this time frame. Successful introduction of this product within our stated timetable should lead to growing confidence in the investing community of LAM`s ability to execute its growth strategy. Other significant products are well past the planning stage and should incrementally add to our revenues and earnings in 2003 and beyond," Slechta concluded.

About LAM Pharmaceutical, Corp.

LAM Pharmaceutical, Corp. is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original Ionic Polymer Matrix(TM) technology (IPM(TM)), a proprietary and patented combination (a total of nine U.S. issued patents) of electrically charged and non-charged molecules with wound-healing properties. IPM(TM) technology combines with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible and thus prolonging therapeutic activity.

The main ingredient of the Ionic Polymer Matrix(TM) technology is a derivative of hyaluronic acid, a molecule normally found in the skin and joints of bones. Hyaluronic acid is a non-immunogenic (the body does not react to it) and it is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars) to optimize tissue repair and prevent tissue aging. As well, hyaluronic acid is present in high concentration in fetal skin where wound healing is rapid and leaves little scarring.

LAM IPM(TM) Wound Gel is a clear, viscous, aqueous, odorless gel composed principally of sodium hyaluronate, a derivative salt of Hyaluronic acid. LAM IPM(TM) Wound Gel has demonstrated in both human and animal trials to be of significant value in the management of certain skin ulcers and wounds where maintaining a moist environment is supportive of the healing process. In human skin, Hyaluronic acid is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars).

As of December 31, 2001, LAM had nine issued patents in the United States. LAM IPM(TM) Wound Gel is protected by one or more of the following patents: 5,887,880; 6,120,804; 6,007,843; 6,063,405. All referenced patents have been issued to LAM Pharmaceutical, Corp. by the United States Patent Office and have subsequently been filed on a global basis.

The Company`s list of products under development include the following:

LAM IPM(TM) -- Extreme Dry Skin Formula -- A gel formula designed to saturate the stratum corneum, to relieve the symptoms of eczema, dermatitis and extremely dry skin.

LAM IPM(TM) -- Female Sexual Dysfunction Matrix -- a product that provides enhanced lubrication while also allowing the external structures of the female genitalia to be flushed with greater blood supply.

LAM IPM(TM) -- Motion Sickness Matrix -- a product currently under development, which is a topically applied delivery system, using a patch, of a well-known motion sickness drug.

LAM IPM(TM) -- Arthritic Pain Matrix -- is a clear aqueous gel that contains a well proven off patent drug.

For more information please visit our website at http://www.lampharm.com or send us an e-mail at [e-mail] to receive the latest information and press releases.

YESSSSSS!!!



GN

[Bombenleger]

Wednesday March 27, 5:00 pm Eastern Time

Press Release

SOURCE: LAM Pharmaceutical, Corp.

LAM IPM(TM) Wound Gel Now Eligible For Medicare Reimbursement

LEWISTON, N.Y., March 27 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt
Stock Exchange: LAM), http://www.lampharm.com announced today that its breakthrough wound care product -- LAM
IPM(TM) Wound Gel -- will be eligible for the Medicare Homecare Reimbursement Plan once it receives FDA approval and is
recommended for use in patients who are being treated by wound care nurses under the cognizance of qualified wound care
professionals.

This highly successful, and fast expanding part of the Medicare system, provides for many patients to be treated at home, instead
of in a much more expensive hospital setting.

LAM IPM(TM) Wound Gel is classified as a hydrogel 510(k) device (FDA Assigned No. K020325) and, as such, home
treatment by specialized wound care nurses is currently paid for by the Medicare system, for this class of product, following
approval by the FDA. Monitoring of individual cases and progress reports are required by medical officials.

Because most patients suffering from severe skin ulcers, including diabetic ulcers, venous stasis ulcers and other severe ulcerated
skin conditions are over the age of 65, and thus are covered by Medicare, LAM Pharmaceutical, Corp. expects to be a major
beneficiary of this highly successful and enlightened Medicare program.

LAM IPM(TM) Wound Gel has enjoyed an 88% success rate in creating an effective moist environment to assist healing in
hard-to-heal ulcers in both animal and human studies while maintaining an extremely low incidence of side effects.

Alan Drizen, C.E.O. of LAM Pharmaceutical, Corp., said, ``We expect a decision from FDA on or about April 30, 2002,
regarding our 510(k) application. Upon receipt of a positive response, management believes that our forecast of US $27 million in
sales for 2003 and US $50 million in sales for 2004 can now be considered conservative. The suitability of our wound care
hydrogel (LAM IPM(TM) Wound Gel) for homecare, under present Medicare guidelines, makes it ideal for homecare use.``

[Testbroker]

Das kenne ich schon alles ! Some News ?